Cargando…
Fbxl17 is rearranged in breast cancer and loss of its activity leads to increased global O-GlcNAcylation
In cancer, many genes are mutated by genome rearrangement, but our understanding of the functional consequences of this remains rudimentary. Here we report the F-box protein encoded by FBXL17 is disrupted in the region of the gene that encodes its substrate-binding leucine rich repeat (LRR) domain....
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320043/ https://www.ncbi.nlm.nih.gov/pubmed/31560077 http://dx.doi.org/10.1007/s00018-019-03306-y |
_version_ | 1783551168027295744 |
---|---|
author | Mason, Bethany Flach, Susanne Teixeira, Felipe R. Manzano Garcia, Raquel Rueda, Oscar M. Abraham, Jean E. Caldas, Carlos Edwards, Paul A. W. Laman, Heike |
author_facet | Mason, Bethany Flach, Susanne Teixeira, Felipe R. Manzano Garcia, Raquel Rueda, Oscar M. Abraham, Jean E. Caldas, Carlos Edwards, Paul A. W. Laman, Heike |
author_sort | Mason, Bethany |
collection | PubMed |
description | In cancer, many genes are mutated by genome rearrangement, but our understanding of the functional consequences of this remains rudimentary. Here we report the F-box protein encoded by FBXL17 is disrupted in the region of the gene that encodes its substrate-binding leucine rich repeat (LRR) domain. Truncating Fbxl17 LRRs impaired its association with the other SCF holoenzyme subunits Skp1, Cul1 and Rbx1, and decreased ubiquitination activity. Loss of the LRRs also differentially affected Fbxl17 binding to its targets. Thus, genomic rearrangements in FBXL17 are likely to disrupt SCF(Fbxl17)-regulated networks in cancer cells. To investigate the functional effect of these rearrangements, we performed a yeast two-hybrid screen to identify Fbxl17-interacting proteins. Among the 37 binding partners Uap1, an enzyme involved in O-GlcNAcylation of proteins was identified most frequently. We demonstrate that Fbxl17 binds to UAP1 directly and inhibits its phosphorylation, which we propose regulates UAP1 activity. Knockdown of Fbxl17 expression elevated O-GlcNAcylation in breast cancer cells, arguing for a functional role for Fbxl17 in this metabolic pathway. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00018-019-03306-y) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-7320043 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-73200432020-07-01 Fbxl17 is rearranged in breast cancer and loss of its activity leads to increased global O-GlcNAcylation Mason, Bethany Flach, Susanne Teixeira, Felipe R. Manzano Garcia, Raquel Rueda, Oscar M. Abraham, Jean E. Caldas, Carlos Edwards, Paul A. W. Laman, Heike Cell Mol Life Sci Original Article In cancer, many genes are mutated by genome rearrangement, but our understanding of the functional consequences of this remains rudimentary. Here we report the F-box protein encoded by FBXL17 is disrupted in the region of the gene that encodes its substrate-binding leucine rich repeat (LRR) domain. Truncating Fbxl17 LRRs impaired its association with the other SCF holoenzyme subunits Skp1, Cul1 and Rbx1, and decreased ubiquitination activity. Loss of the LRRs also differentially affected Fbxl17 binding to its targets. Thus, genomic rearrangements in FBXL17 are likely to disrupt SCF(Fbxl17)-regulated networks in cancer cells. To investigate the functional effect of these rearrangements, we performed a yeast two-hybrid screen to identify Fbxl17-interacting proteins. Among the 37 binding partners Uap1, an enzyme involved in O-GlcNAcylation of proteins was identified most frequently. We demonstrate that Fbxl17 binds to UAP1 directly and inhibits its phosphorylation, which we propose regulates UAP1 activity. Knockdown of Fbxl17 expression elevated O-GlcNAcylation in breast cancer cells, arguing for a functional role for Fbxl17 in this metabolic pathway. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00018-019-03306-y) contains supplementary material, which is available to authorized users. Springer International Publishing 2019-09-27 2020 /pmc/articles/PMC7320043/ /pubmed/31560077 http://dx.doi.org/10.1007/s00018-019-03306-y Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Mason, Bethany Flach, Susanne Teixeira, Felipe R. Manzano Garcia, Raquel Rueda, Oscar M. Abraham, Jean E. Caldas, Carlos Edwards, Paul A. W. Laman, Heike Fbxl17 is rearranged in breast cancer and loss of its activity leads to increased global O-GlcNAcylation |
title | Fbxl17 is rearranged in breast cancer and loss of its activity leads to increased global O-GlcNAcylation |
title_full | Fbxl17 is rearranged in breast cancer and loss of its activity leads to increased global O-GlcNAcylation |
title_fullStr | Fbxl17 is rearranged in breast cancer and loss of its activity leads to increased global O-GlcNAcylation |
title_full_unstemmed | Fbxl17 is rearranged in breast cancer and loss of its activity leads to increased global O-GlcNAcylation |
title_short | Fbxl17 is rearranged in breast cancer and loss of its activity leads to increased global O-GlcNAcylation |
title_sort | fbxl17 is rearranged in breast cancer and loss of its activity leads to increased global o-glcnacylation |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320043/ https://www.ncbi.nlm.nih.gov/pubmed/31560077 http://dx.doi.org/10.1007/s00018-019-03306-y |
work_keys_str_mv | AT masonbethany fbxl17isrearrangedinbreastcancerandlossofitsactivityleadstoincreasedglobaloglcnacylation AT flachsusanne fbxl17isrearrangedinbreastcancerandlossofitsactivityleadstoincreasedglobaloglcnacylation AT teixeirafeliper fbxl17isrearrangedinbreastcancerandlossofitsactivityleadstoincreasedglobaloglcnacylation AT manzanogarciaraquel fbxl17isrearrangedinbreastcancerandlossofitsactivityleadstoincreasedglobaloglcnacylation AT ruedaoscarm fbxl17isrearrangedinbreastcancerandlossofitsactivityleadstoincreasedglobaloglcnacylation AT abrahamjeane fbxl17isrearrangedinbreastcancerandlossofitsactivityleadstoincreasedglobaloglcnacylation AT caldascarlos fbxl17isrearrangedinbreastcancerandlossofitsactivityleadstoincreasedglobaloglcnacylation AT edwardspaulaw fbxl17isrearrangedinbreastcancerandlossofitsactivityleadstoincreasedglobaloglcnacylation AT lamanheike fbxl17isrearrangedinbreastcancerandlossofitsactivityleadstoincreasedglobaloglcnacylation |